(TheNewswire)
Vancouver, B.C. / TheNewswire / November 10, 2017 – Veritas Pharma Inc
. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, announces that it
has issued 1,300,000 options to consultants of the Company under the stock option plan at an exercise price of $0.44 for a period
of 1 year from the date of the grant.
About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging-stage pharmaceutical and IP development company, who, through
Cannevert Therapeutics Ltd. (“CTL”), is advancing the science behind medical cannabis. It is the Company aim, through its
investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving
the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research
and development model to help drive shareholder value, and speed-to-market. Veritas investment in CTL is led by strong management
team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent
protect CTL’s IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting
multi-billion dollar global markets.
Veritas Pharma Inc. is a publicly traded company which trades in three countries including Canada,
on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on
the Frankfurt exchange under the ticker 2VP.
For more information, please visit our website: www.veritaspharmainc.com
On behalf of the Board of Directors; Veritas Pharma Inc.
"Dr. Lui Franciosi"
Dr. Lui Franciosi
Chief Executive Officer
Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at
www.sedar.com and on the CSE website at www.thecse.com
Investor and Public Relations Contact
Veritas Pharma Inc.
Sam Eskandari
Telephone: +1.416.918.6785
Email: ir@veritaspharmainc.com
Website: www.veritaspharmainc.com
The CSE has not reviewed, nor approved or disapproved the content of this press
release.
Copyright (c) 2017 TheNewswire - All rights reserved.